ES2742179T3 - Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino - Google Patents

Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino Download PDF

Info

Publication number
ES2742179T3
ES2742179T3 ES15731560T ES15731560T ES2742179T3 ES 2742179 T3 ES2742179 T3 ES 2742179T3 ES 15731560 T ES15731560 T ES 15731560T ES 15731560 T ES15731560 T ES 15731560T ES 2742179 T3 ES2742179 T3 ES 2742179T3
Authority
ES
Spain
Prior art keywords
ox1r
seq
colitis
disease
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15731560T
Other languages
English (en)
Spanish (es)
Inventor
Alain Couvineau
Thierry Voisin
Nassima Messal
Eric Ogier-Denis
Xavier Treton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Diderot - Paris 7
Original Assignee
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Diderot - Paris 7
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Université Paris Diderot - Paris 7 filed Critical Assistance Publique - Hôpitaux de Paris
Application granted granted Critical
Publication of ES2742179T3 publication Critical patent/ES2742179T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES15731560T 2014-06-24 2015-06-23 Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino Active ES2742179T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305990 2014-06-24
PCT/EP2015/064028 WO2015197572A1 (en) 2014-06-24 2015-06-23 Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases

Publications (1)

Publication Number Publication Date
ES2742179T3 true ES2742179T3 (es) 2020-02-13

Family

ID=51062760

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15731560T Active ES2742179T3 (es) 2014-06-24 2015-06-23 Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino

Country Status (5)

Country Link
US (1) US10172921B2 (enExample)
EP (1) EP3169348B1 (enExample)
JP (1) JP6697403B2 (enExample)
ES (1) ES2742179T3 (enExample)
WO (1) WO2015197572A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017064302A1 (en) * 2015-10-16 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
CA3003283A1 (en) * 2015-11-24 2017-06-01 Theravance Biopharma R&D Ip, Llc Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
EP3454857A1 (en) * 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
EP4097119B1 (en) 2020-01-31 2025-05-07 The Johns Hopkins University Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases
WO2021156310A1 (en) * 2020-02-04 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Tafa4 polypeptide or polynucleotide for treating inflammatory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000787A2 (en) 1999-06-25 2001-01-04 Smithkline Beecham Corporation Methods of treatment using lig 72a and variants thereof
WO2004082715A1 (ja) * 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
KR20100057063A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도

Also Published As

Publication number Publication date
EP3169348B1 (en) 2019-07-31
WO2015197572A1 (en) 2015-12-30
JP2017520554A (ja) 2017-07-27
US20170202925A1 (en) 2017-07-20
EP3169348A1 (en) 2017-05-24
JP6697403B2 (ja) 2020-05-20
US10172921B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
EP3169348B1 (en) Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases
ES3064852T3 (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
JP2011530599A5 (enExample)
BR112021010982A2 (pt) Ligantes
US20260091083A1 (en) Cyclic prosaposin peptides and uses thereof
WO2019086676A1 (en) IL13Rα2 PEPTIDE AND ITS USES
JP5699077B2 (ja) 遺伝子組み換えゼラチンを含む腎臓標的ドラッグデリバリー剤
JP2023537163A (ja) 細胞内の腫瘍誘発タンパク質をターゲットとする抗体又はその単一鎖可変断片と癌細胞透過性ペプチドの融合タンパク質及びその用途
CN102746380A (zh) 血管生成抑制剂多肽在制备治疗肿瘤及类风湿性关节炎药物中的应用
EP2253326B1 (en) Pharmaceutical composition for transnasal administration
CN105693864A (zh) 一种三聚体trail蛋白及其应用
ES3040184T3 (en) Fusion protein preparation comprising il-2 and cd80 proteins
CN118369351A (zh) Dsg2组合物和方法
ES2857704T3 (es) Vacunación/radioterapia combinadas para el tratamiento del cáncer
HK40090948A (en) Cyclic prosaposin peptides and uses thereof
WO2025024343A2 (en) Cleavable polymer-drug conjugates for alzheimer's disease
CA2943802C (en) Cyclic prosaposin peptides and uses thereof
CN104136038A (zh) 体腔积液抑制剂
HK1223556A1 (zh) Il-22二聚体在制备用於治疗胰腺炎的药物中的用途
HK1233930B (en) Cyclic prosaposin peptides and uses thereof
HK1233930A1 (en) Cyclic prosaposin peptides and uses thereof